← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $611B	2,104	-18	-0.8%	$185B
2	2 Pfizer PFE $168B	1,877	+16	+0.9%	$155B
3	3 Merck MRK $359B	1,712	-11	-0.6%	$121B
4	4 AbbVie ABBV $501B	1,601	-5	-0.3%	$65.3B
5	5 Gilead Sciences GILD $195B	1,494	+53	+4%	$121B
6	6 Bristol-Myers Squibb BMY $124B	1,450	+39	+3%	$77.7B
7	7 Amgen AMGN $235B	1,345	+4	+0.3%	$98.5B
8	8 Novartis NVS $286B	940	+21	+2%	$23.1B
9	9 GSK GSK $98.3B	741	+12	+2%	$11.6B
10	10 Regeneron Pharmaceuticals REGN $82B	509	-3	-0.6%	$32.9B
11	11 AstraZeneca AZN $258B	386	-18	-4%	$6.15B
12	12 Jazz Pharmaceuticals JAZZ $13.9B	355	-3	-0.8%	$9.07B
13	13 Incyte INCY $22.9B	304	+20	+7%	$15.3B
14	14 Myriad Genetics MYGN $415M	252	-21	-8%	$3.31B
15	SGEN 15 DELISTED Seagen Inc. Common Stock SGEN	203	-11	-5%	$4.47B
16	16 Puma Biotechnology PBYI $543M	199	+10	+5%	$6.87B
17	17 DELISTED Assertio ASRT	196	+28	+17%	$1.38B
18	18 Opko Health OPK $1.2B	191	+15	+9%	$1.14B
19	19 DELISTED Exact Sciences EXAS	182	-16	-8%	$1.93B
20	20 Precigen PGEN $2.58B	154	+46	+43%	$4.29B
21	CLVS 21 DELISTED Clovis Oncology, Inc. CLVS	152	+9	+6%	$2.41B
22	22 DELISTED Merrimack Pharmaceuticals, Inc. MACK	152	+9	+6%	$820M
23	23 DELISTED Chimerix, Inc. CMRX	142	+12	+9%	$1.36B
24	24 DELISTED Immunogen Inc IMGN	141	+10	+8%	$664M
25	INFI 25 DELISTED Infinity Pharmaceuticals, Inc. INFI	141	-2	-1%	$692M